Bioethics appoints Doug Morris to Board and as VP of Corporate Development

BIOETHICS LTD

Doug Morris appointed to Board of Directors and as VP of Corporate Development on April 26, 2024.
Morris is co-founder of Bio-Path Holdings (BPTH) and served as a director since 2007 and officer until 2014.
Currently serves as Director of Investor Relations and Secretary of Bio-Path Holdings.
His other roles include officer/director at Spirits Time International and managing member of Sycamore Ventures.
Will serve until next annual meeting, earlier resignation, or death.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Doug Morris

Director

BIOETHICS LTD

Effective: 2024-04-26
Filed: April 30, 2024, 7:59 PM ET

On April 26, 2024, Doug Morris was appointed to serve as a member of our Board of Directors

Appointed

Doug Morris

Vice President of Corporate Development

BIOETHICS LTD

Effective: 2024-04-26
Filed: April 30, 2024, 7:59 PM ET

Mr. Morris was also appointed as our Vice President of Corporate Development

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Doug Morris was appointed as Director at BIOETHICS LTD.

Action: appointed
Role: Director

Exact text from the filing

On April 26, 2024, Doug Morris was appointed to serve as a member of our Board of Directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Doug Morris was appointed as Vice President of Corporate Development at BIOETHICS LTD.

Action: appointed
Role: Vice President of Corporate Development

Exact text from the filing

Mr. Morris was also appointed as our Vice President of Corporate Development

View on SEC.gov

Source: SEC EDGAR

accession 0001551163-24-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.